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Abstract
S100A7 is a small calcium binding protein, which has been shown to be differentially expressed in psoriatic skin lesions, as
well as in squamous cell tumors of the skin, lung and breast. Although its expression has been correlated to HER+ high-
grade tumors and to a high risk of progression, the molecular mechanisms of these S100A7-mediated tumorigenic effects
are not well known. Here, we showed for the first time that epidermal growth factor (EGF) induces S100A7 expression in
both MCF-7 and MDA-MB-468 cell lines. We also observed a decrease in EGF-directed migration in shRNA-downregulated
MDA-MB-468 cell lines. Furthermore, our signaling studies revealed that EGF induced simultaneous EGF receptor
phosphorylation at Tyr1173 and HER2 phosphorylation at Tyr1248 in S100A7-downregulated cell lines as compared to the
vector-transfected controls. In addition, reduced phosphorylation of Src at tyrosine 416 and p-SHP2 at tyrosine 542 was
observed in these downregulated cell lines. Further studies revealed that S100A7-downregulated cells had reduced
angiogenesis in vivo based on matrigel plug assays. Our results also showed decreased tumor-induced osteoclastic
resorption in an intra-tibial bone injection model involving SCID mice. S100A7-downregulated cells had decreased
osteoclast number and size as compared to the vector controls, and this decrease was associated with variations in IL-8
expression in in vitro cell cultures. This is a novel report on the role of S100A7 in EGF-induced signaling in breast cancer cells
and in osteoclast formation.
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Introduction
S100A7 (also known as psoriasin) is a small calcium binding
protein of 11 kDa molecular weight, first described as an mRNA
expressed in psoriatic skin lesions [1]. It is a member of the S100
family of the EF-hand type of calcium binding proteins. The
S100A7 protein is known to be expressed in various tumors having
squamous differentiation as a major component with or without
accompanying inflammation (eg, squamous cell carcinoma of the
skin [2,3], lung [4], cervix, bladder [5] and breast as well as
adenocarcinoma of the breast [6]. S100A7 was identified as a
differentially expressed gene in ductal carcinoma in-situ (DCIS)
but not in invasive breast carcinomas, suggesting its potential role
in tumor progression. Expression of S100A7 has been shown to be
correlated with HER+, high-grade tumors [6]. The high
expression level of S100A7 in poorly differentiated and lymph
node positive breast tumors suggests that it may predict poor
clinical outcome and a high risk of recurrence or progression in
DCIS [7]. Although S100A7 has been reported to play a role in
breast cancer, the molecular mechanisms of its effects are not well
known. Recent studies have suggested that EGF may regulate
S100A7 expression [8].
EGF and its related family member, HER2/Neu, are
commonly expressed in breast cancers, including in 60% of
invasive breast cancers. Overexpression of HER2 was previously
linked to DCIS [9]. In addition, overexpression of EGF was
correlated with tumor progression and extensive metastasis in
breast cancers [10], and other malignancies [11]. Breast
carcinomas with squamous differentiation are a distinct subgroup
of breast tumors with a high frequency of EGF receptor positivity
[12]. EGFR is a 170 kDa Type 1 transmembrane glycoprotein
containing an extracellular ligand-binding domain, transmem-
brane domain, and a cytoplasmic tail, which includes a tyrosine
kinase domain and docking sites for binding [13].
Tumor angiogenesis plays an important role in tumor growth
and metastasis. In the past two decades, numerous positive and
negative regulators of angiogenesis have been described, the most
recent one being VEGF. High VEGF levels have been detected in
S100A7-overexpressing cells and these levels were correlated with
increased tumor angiogenesis in human breast tumors [14].
The bone is the first site of metastasis in 25–50% of breast cancer
cases and osteolytic lesions are present in 70–80% of patients with
stage IV breast cancer [15,16]. Histological analysis and scanning
microscopy have revealed that bone destruction is mediated by
PLoS ONE | www.plosone.org 1 March 2008 | Volume 3 | Issue 3 | e1741osteoclasts. Tyrosine kinase inhibitors of EGFR have been shown to
efficiently block the in vitro and in vivo activation of this receptor, and
to significantly inhibit tumor growth in experimental animal
models. Tumor cells, osteoclasts, stromal cells and the extracellular
matrix are components required for the initiation and development
of bone metastasis. Tumor cells activate osteoclasts via PTHrP, IL-
6, IL-1, and TNF-a. PTHrP-independent factors like IL-11 and IL-
8 also contribute to osteolytic activity [17]. Moreover, IL-8 is a
major osteolytic factor and potent activator of bone destruction
accompanying metastatic bone disease [18].
Our study for the first time reveals that S100A7 may regulate
EGF-induced EGFR phosphorylation and other downstream
signaling molecules. We found that S100A7-downregulated breast
cancer cells exhibited a reduction in EGF-induced chemotaxis and
invasion on matrigel-coated transwells. Furthermore, we showed
that S100A7 reduced the number and size of osteoclasts formed in
vitro and the size of osteolytic lesions observed in vivo. We also noted
decreased angiogenesis in matrigel assays utilizing S100A7-
downregulated cells. This is a novel report indicating the role of
S100A7 in EGFR signaling and osteoclast resorption.
Results
Growth factors regulate S100A7 expression
Recently, it has been shown that S100A7 is associated with an
increase in EGF mRNA levels [8]. However, not much is known
about growth factor effects on S100A7 expression in malignant
breast tissues. Thus, we analyzed the effect of EGF on S100A7
expression in MCF-7 and MDA-MB-468 breast cancer cell lines.
EGF increased the expression of S100A7 in a dose-dependent
manner in both MCF-7 cells (Figure 1A) and MDA-MB-468 cells
(Figure 1B). Peak effect was seen between 70–100 ng/ml of EGF.
S100A7 silencing by S100A7 shRNA inhibits EGF-induced
cell migration and invasion
To investigate the involvement of S100A7 in the EGF-mediated
effects on migration and invasion, we used stable S100A7-shRNA-
downregulated cells (Figure 2A), as previously reported [14]. We
observed a reduction in both EGF-induced cell migration on
fibronectin-coated plates in Boyden chambers (Figure 2B) and
invasive activity on matrigel-coated plates (Figure 2C). The
migration of the S100A7-downregulated cells towards EGF was
significantly reduced (by 40%) as compared to the vector-
transfected controls.
S100A7 mediates EGFR/HER2 cell signaling through
distinct and specific phosphorylation of tyrosine residues
and downstream cascading events
In order to evaluate the role of S100A7 in EGF-mediated
signaling, we compared EGFR phosphorylation as well as the
activities of various downstream signaling molecules in S100A7-
vector control and S100A7-downregulated cell lines. Previously, it
was shown that on ligand binding, EGFR activation involves
homo- and hetero-dimerization with other EGFR family members
(such as HER2), transphosphorylation of receptors, and activation
of a number of different downstream signaling pathways [19–21].
EGFR expression has also been linked to activation of ErbB2 in
human breast cancers [22]. In our study, phosphorylations of
EGFR Tyr1173 and HER2 Tyr1248 (Figure 3A), EGFR Tyr1173
(Figure 3B), and Tyr1068 (data not shown) were reduced in
S100A7-downregulated cells as compared to empty vector-
transfected cell lines following treatment with increasing concen-
trations of EGF. A peak effect on phosphorylation was observed
between 70–100 ng/ml of EGF. EGFR expression combined with
c-Src overexpression can initiate oncogenic transformation and
marked migratory and invasive behavior in human breast cancer
cells [23]. We observed a decrease in Src phosphorylation at
Tyr416 in EGF-stimulated S100A7-downregulated cells as
compared to the control cells (Figure 3C). Moreover, since the
tyrosine phosphatase SHP2 acts as an important positive regulator
of EGFR signaling and is associated with signals initiated by
receptor tyrosine kinases, we next evaluated SHP2 phosphoryla-
tion in the EGF-stimulated S100A7-downregulated cell lines as
compared to the empty vector controls. SHP2 phosphorylation at
Tyr542 was reduced in the S100A7-downregulated cells
(Figure 3D). These results indicate that S100A7 alters EGF
downstream signaling pathways.
S100A7 downregulation reduces angiogenesis in a
matrigel plug assay
It has been shown that S100A7 overexpression increases VEGF
expression levels (8) and that downregulation of S100A7 decreases
the expression of VEGF [14]. In addition, a correlation was
observed between high S100A7 expression and the angiogenic
marker CD31 in samples derived from human breast cancer [14].
Thus, we examined the effect of S100A7 on angiogenic potential
in SCID mice by using a matrigel plug assay. After 4 weeks, the
matrigel plugs were either fixed for histology or extracted for
hemoglobin. Evaluation of the matrigel plugs revealed a decrease
in the number of blood vessels in the plugs from the S100A7-
downregulated cells versus the control plugs, as detected by CD31
staining (Figure 4A). The inhibited blood vessel formation also
resulted in a significant decrease in blood volume in the S100A7-
downregulated cells containing the plugs, as measured by
hemoglobin assays (Figure 4B).
Downregulation of S100A7 decreases bone osteolysis
It has been shown that downregulation of S100A7 expression
markedly decreases in vivo tumorigenicity and lung metastasis [14].
Figure 1. EGF stimulation enhances S100A7 expression in
breast cancer cells. 70–80% confluent MCF-7 cells (A) and MDA-MB-
468 cells (B) were washed twice and rinsed with PBS followed by 18 hrs
of serum starvation. The cells were then stimulated with various
concentrations of epidermal growth factor (EGF) for 30 minutes at 37uC.
The cells were lysed and S100A7 expression was analyzed by Western
blotting with anti-S100A7 antibody, as indicated. Equal protein loading
in each lane was checked by stripping the blots and probing with b-
Actin antibody (A and B, lower panels). The experiments were repeated
thrice with identical results.
doi:10.1371/journal.pone.0001741.g001
S100A7, EGF-Induced Signaling
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metastatic bone lesions and osteoclast formation at the site of
metastasis is not known. Breast cancer cells that metastasize to the
bone commonly cause osteolytic lesions, which are mediated by
osteoclasts. Direct injection of cancer cells into mouse bone has
been used as a model to analyze bone metastasis in renal
carcinoma [24] and prostate cancer [25]. Here, we employed the
orthotopic bone implantation model to analyze the formation of
osteolytic lesions in mice. Intra-tibial injections in mice were
carried out as described in Materials and Methods. We observed
osteolytic lesions as well as destruction of the cortex, with tumors
Figure 2. S100A7 knocked-down MDA-MB-468 cells show a
decrease in EGF-induced migration and invasion. (A) MDA-MB-
468 cells were transfected with vector control or S100A7-shRNA, as
described in Materials and Methods. S100A7 expression in these cells
was analyzed by Western blotting with anti-S100A7 antibody (upper
panel). Equal protein loading in each lane was checked by stripping the
blot and probing with b-Actin antibody (lower panel). (B) Control and
S100A7 shRNA-transfected MDA-MB-468 cells were subjected to a
chemotaxis assay towards EGF (20 ng/ml) using the modified Boyden
chamber assay, as described in Materials and Methods. The lower
surface of the insert was stained with the Diff-Quik Stain kit and cells
were counted in an average of 5 high-power fields (HPF; 206).
Experiments were done in triplicate and repeated three times with
similar results. *p,0.05 (C) Control and S100A7 shRNA-transfected
MDA-MB-468 cells were subjected to an invasion assay using matrigel-
coated transwell plates (BD Biosciences). Chemotaxis towards EGF
(20 ng/ml) was then analyzed, as described in Materials and Methods.
The cells on the insert were stained with the Diff-Quik Stain kit and total
cell numbers were counted (106). Experiments were done in triplicate
and repeated thrice with similar results. *p,0.05.
doi:10.1371/journal.pone.0001741.g002
Figure 3. S100A7 downregulation decreases the phosphoryla-
tion of EGFR/HER2, Src and SHP2 in MDA-MB-468 cell lines.
Vector control and S100A7-shRNA stably-transfected MDA-MB-468 cell
lines were starved overnight and stimulated with various concentra-
tions of EGF (0 to 100 ng/ml) for 30 minutes at 37uC. The cells were
then lysed and the lysates were analyzed by Western blotting with p-
EGFR Tyr1173/p-HER2 Tyr1248 (A, upper panel) or p-EGFR Tyr1173 (B,
upper panel) antibodies. The protein levels were monitored by
stripping the blots with anti-EGFR antibody (A and B, lower panels).
Vector-transfected controls and S100A7 shRNA-transfected stable MDA-
MB-468 cell lines were starved overnight for 17 hours and stimulated
with various concentrations of EGF (0 to 100 ng/ml) for 15 minutes at
37uC. The cells were then lysed and the lysates were analyzed by
Western blotting with p-Src Tyr416 (C, upper panel) or p-SHP2 Tyr542
antibody (D, upper panel). The protein levels were monitored by
stripping the blots with total Src and SHP2 antibodies, as indicated (C
and D, lower panels).
doi:10.1371/journal.pone.0001741.g003
S100A7, EGF-Induced Signaling
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with the S100A7-control cells (Figure 5, Panels A1 and A2). The
cortex on both sides was intact in mice injected with the S100A7-
downregulated cells (Figure 5, Panels B1 and B2). H & E
sectioning showed loss of the trabecular meshwork in the proximal
tibia in the control group as compared to the S100A7-
downregulated group (Figure 5: Panels C1 and C2, respectively).
This result suggests that S100A7 may play a role in tumor-induced
bone resorption.
S100A7 downregulation decreases osteoclast formation
in transwell assays
Since we observed reduced osteolytic lesions in mice injected
with S100A7-downregulated cells, we analyzed the role of S100A7
in osteoclast formation. Osteoclasts are known to mediate
osteolytic lesions at the sites of metastatic tumors. Precursor
osteoclasts, prepared from bone marrow cultures (as described in
Materials and Methods), were placed in 24-well plates and inserts
containing vector control or S100A7-shRNA-downregulated
breast cancer cells (5610
4 cells) were placed in the wells. Addition
of RANKL without breast cancer cells served as a control. We
observed a marked increase in osteoclast formation and fusion as
measured by the number and size of TRAP+ multinucleated (.3
nuclei) giant cells in the S100A7 control cells as compared to the
downregulated cells (Figure 6A and B).
Reduced IL-8 expression is present in S100A7-
downregulated cell lines
Tumor cells secrete IL-8 which is known to stimulate the
formation of osteoclasts from hematopoietic precursors in the bone
marrow, resulting in increased osteoclastic bone resorption [18].
Furthermore, metastatic cells isolated from bone have been shown
to produce greater amounts of IL-8 [17]. Therefore, we analyzed
IL-8 production in the conditioned media of control and S100A7-
downregulated cell lines. We observed a statistically significant
decrease in IL-8 levels in the conditioned media of S100A7-
Figure 4. S100A7-downregulation decreases angiogenesis. (A)
Effect of S100A7 on blood vessel formation in matrigel plugs containing
MDA-MB-468 cell lines. 250 ml of Growth factor-reduced Matrigel Matrix
High Concentration (BD Biosciences) was mixed with 6610
6 cells
(250 ml of vector control or 250 ml of S100A7-downregulated cells) and
implanted subcutaneously into SCID mice (two sites per mouse). After
4 weeks, one matrigel plug from each mouse injected with vector
control or S100A7-shRNA cells was fixed in Tissue Tek and snap-frozen.
The sections were stained for CD31 antibody by immunohistochemistry.
(B) The other plug was grounded and the supernatant was analyzed for
hemoglobin content using the Hemoglobin Assay Kit (Sigma Diagnos-
tics). The results are interpreted as the blood volume per unit weight of
matrigel (* p,0.05).
doi:10.1371/journal.pone.0001741.g004
Figure 5. S100A7 downregulation decreases osteolytic lesions
in vivo. Cells were directly introduced into the tibias of 4 week-old
mice, as described in Materials and Methods. Micro-CT scanning of live
mice was done using a GE eXplore Micro-CT scanner (GE Healthcare Ltd,
UK) at 93 mm resolution, 6 weeks after injection. The tibias were
dissected out and scout view radiographs were taken with a micro-CT40
scanner at 12 mm resolution obtained from SCANCO Medical AG
(Switzerland). There were osteolytic lesions, destruction of the cortex
and extension of the tumor into the soft tissue in the mice injected with
the control S100A7 cells (Panels A1 and A2). The cortex of the mice
injected with the S100A7-downregulated cells was intact (Panels B1 and
B2). Tibias were excised and processed for conventional histological
examination. S100A7 control mice showed tumor-induced osteolysis
(Panel C1), and the osteolysis was evident in all three injected mice as
compared to mice injected with the S100A7-downregulated cells (Panel
C2) (H & E staining, 206). The letter ‘T’ in panel C1 represents tumor.
The experiments were repeated twice with identical results.
doi:10.1371/journal.pone.0001741.g005
S100A7, EGF-Induced Signaling
PLoS ONE | www.plosone.org 4 March 2008 | Volume 3 | Issue 3 | e1741downregulated cells as compared to S100A7 vector control cells
(Figure 6C).
Discussion
S100A7 is a member of the S100 family of proteins, which have
been associated with preinvasive DCIS. Persistent expression of
S100A7 occurs in some invasive cancers and is associated with poor
prognostic factors [6]. Persistent S100A7 expression also occurs in a
subset of invasive breast carcinomas and is linked to worse clinical
outcome [26]. S100A7 has been shown to be overexpressed in
breast cancers at sites of necrosis in tumor tissues [6,8], as well as in
the nasal fluid during allergic inflammatory reactions [27].
Although S100A7 has been reported to increase EGF mRNA
levelsinMDA-MB-231cells[8], not much is knownabout itsrole in
EGF-induced EGFR signaling. In the present study, we have shown
that S100A7 modulates EGFR-induced phosphorylation, migration
and functional effects. We also characterized EGFR’s influence on
S100A7 expression and its role in the EGF-induced metastasis and
invasion of breast cancer cells.
Our experiments show the importance of S100A7 in EGF-
induced and EGFR-mediated expression, signaling and migration.
Figure 6. S100A7-downregulated cells decrease osteoclast formation and IL-8 expression levels. Osteoclast precursors were prepared
(as described in Materials and Methods), plated in 24-well plates and allowed to stand for 5–6 hours. (A) Inserts containing 5610
4 vector control cells,
the S100A7 shRNA (downregulated) cells or RANKL without breast cancer cells (internal positive control) were then placed on the wells and the
numbers of TRAP+ multinucleated cells generated under each condition were counted at the end of 48 hours. Each culture was done in triplicate.
The experiments were repeated thrice with similar results. (B) The number of multinucleated fused osteoclast cells (A) in an average of triplicate wells
is represented in the histogram. Results are expressed as the mean6SEM (*p,0.05). (C) Vector control and S100A7 shRNA-transfected stable MDA-
MB-468 cell lines were grown to 80% confluence and supernatants were analyzed for IL-8 expression by ELISA. IL-8 expression was significantly less
(*p,0.02) in the S100A7-downregulated cells as compared to the vector-transfected controls.
doi:10.1371/journal.pone.0001741.g006
S100A7, EGF-Induced Signaling
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cell lines following EGF stimulation. We observed a significant
inhibition of EGF-induced migration on fibronectin-coated plates
in S100A7-downregulated cell lines. There was also decreased
EGF-directed invasion on matrigel-coated transwells. The results
are in agreement with previous studies which reported a 1.4-fold
increase in invasiveness in S100A7-overexpressing MDA-MB-231
clones [28]. However, different results were reported by other
investigators [14] who observed an increase in the migration and
invasion of S100A7-downregulated cells as compared to vector
control cells. The absence of growth factors or serum in the above
experiments could explain the differences in cell migration and
invasion observed in those studies.
EGFR-mediated signaling has been correlated with disease
stage and the development of tumor metastasis in breast cancer.
We have observed that S100A7 regulates EGF-induced signaling.
We noted a decrease in EGFR/HER2 phosphorylation at
Tyr1068, Tyr1173, and Tyr1248 (HER2) sites in S100A7-
downregulated MDA-MB-468 cells as compared to empty
vector-transfected control cells upon EGF stimulation. Tyr1173
corresponds to the main site of EGFR autophosphorylation and
has been shown to be critical for the tyrosine kinase activity of
EGFR as well as its ability to mediate actions in response to EGF
[29]. Tyr1068 and Tyr1248 are considered to be major in vitro
autophosphorylation sites of EGFR and HER2, respectively [30].
Furthermore, Tyr1173 (EGFR) is known to be involved in radio-
resistance and has also been shown to phosphorylate key
intracellular molecules like GAB1, SHC and PLC-c, which play
a role in cell survival and migration in concert with HER2
receptors. Both HER2 and EGFR tyrosine kinase activation are
known to predict the efficacy of trastuzumab-based therapy in
patients with metastatic breast cancer [31].
The SHP2 tyrosine phosphatase acts as an important positive
regulator of EGFR signaling [32]. We observed a dose-dependent
decrease in SHP2 phosphorylation (at Tyr542) in EGF-stimulated
S100A7-downregulated cell lines as compared to empty vector
controls (Figure 3D). Tyr542 is the major Grb2 binding site in
tyrosyl-phosphorylated SHP2. Phosphorylation of SHP2 at
Tyr542 has been reported to stimulate its activity by 3-fold [33].
It has also been shown that SHP2 is necessary for ErbB2 to
activate c-Src. Elevated Src expression is frequently observed in
human breast cancer tissues compared with benign breast tumors
or adjacent normal breast tissues and this elevated Src activity has
been correlated with high grade, high proliferation and HER2
positivity in DCIS [34] as well as with poor metastasis-free survival
in invasive breast cancers [35,36]. Reduction in the amount of c-
Src and subsequently that of EGFR activity has been shown to
decrease invasion [37]. We have seen decreased phosphorylation
of c-Src at Tyr416 in S100A7-downregulated cell lines as
compared to vector-transfected controls. Tyr416 of Src is located
in the kinase domain and phosphorylation of Src at this site
enhances its catalytic activity. Thus, these data support a role for
S100A7 as a modulator of the growth effects of EGF, which may
have clinical implications in a subset of breast carcinomas where
EGFR is overexpressed.
Suppression of EGFR signaling by EGFR inhibitors is known to
reduce the incidence of prostate cancer metastasis to the bone in
nude mice models [25]. The bone is a common site of metastases
from breast, prostate, renal and thyroid cancers. Tumor growth in
the bone depends on osteoclastic activity, which increases bone
resorption and releases growth factors sequestrated in the bone
matrix [38]. Most (,85%) of breast cancer lesions are osteolytic in
nature [39], in contrast to bone secondaries from prostate cancer
which are osteosclerotic. Tumor cells induce these lesions directly
by secreting factors that increase mature osteoclasts in the bone or
indirectly through stromal cells, which secrete growth factors and
cytokines causing the differentiation of precursors to active
osteoclasts [16,40]. Since the MDA-MB-468 cell line is not highly
metastatic, it did not produce bone metastasis or gross visible lung
metastasis on intravenous injections in our study. Therefore, we
injected vector control cells and S100A7-downregulated cells into
the tibia of mice to determine if S100A7 is involved in the
osteoclast resorption of bone. We observed significant lytic lesions
in the tibia with destruction of the cortex on CT imaging in
control mice and few lytic lesions in mice injected with the
S100A7-downregulated cells. The marrow and trabecular bones
were destroyed in the proximal tibia of the control mice as
compared to the tibia from mice with S100A7-downregulation,
where the marrow cavity and trabecular bones remained intact.
This suggests that S100A7 may play an important role in the
formation of osteolytic lesions and hence in the metastasis of breast
cancer cells to bone.
The development and progression of osteolytic lesions in the
bone is a complex phenomenon involving tumor cell interaction
with different cell types of the bone microenvironment [41]. We
used an in vitro model involving osteoclast activation by breast
cancer cells to confirm our in vivo findings. Human osteoclast
precursors, isolated from mouse bone marrow, were differentiated
into TRAP+ multinucleated cells, which were larger in size and
number in the S100A7-control breast cancer cells as compared to
the S100A7-downregulated cells in transwell assays. Breast cancer
cells are able to synthesize many growth factors and cytokines that
can lead to the activation of osteoclasts [38]. Several cytokines
have been implicated in the invasiveness of breast tumors [42].
Low expression of IL-8 was seen in the supernatants of S100A7-
downregulated cells. High IL-8 expression has been correlated
with increased invasiveness and angiogenesis. Expression of
IL-8 was also correlated with increased bone metastasis in a
population of breast cancer cells [18], and tumors isolated
from bone metastatic sites were reported to show high IL-8
secretion [43]. The latter was mediated through COX-2. In
addition to the above in vivo findings, IL-8 has been demonstrated
to have direct stimulatory effects on human osteoclastogenesis and
bone resorption [17]. Breast cancer cells with high VEGF
expression also have high IL-8 expression levels [44], which
correlates with our data showing increased tumor growth and
aggressiveness in S100A7-control cell lines as compared to
S100A7-downregulated cell lines. Our in vitro results support our
in vivo findings of increased osteolytic lesions in the S100A7 control
group.
We observed that S100A7 expression was associated with
increased blood vessel density in mouse models of human breast
cancer. We demonstrated a reduction in angiogenesis in vivo as
determined by decreased microvascular density in the histological
sections of matrigel plugs containing S100A7-downregulated cells
and high-concentration growth factor-reduced matrigel as com-
pared to the S100A7-vector control cells when injected into mice.
Our in vivo findings concur with a previous study which reported
that S100A7-downregulated tumors have reduced VEGF expres-
sion in vitro as compared to vector-transfected control cells, and
that human breast cancer tissues with decreased S100A7
expression levels have reduced CD31 staining [14]. Inhibition of
blood vessel formation resulted in a significant decrease in blood
volume in the S100A7-downregulated plugs. This was due to the
reduced size of the tumor. However, when we compared blood
volume per gram of tissue, the volume was decreased by 60% in
the plugs from mice with S100A7-downregulation. Increased
microvascular density has been correlated with active EGFR,
S100A7, EGF-Induced Signaling
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HER2 expression in breast tumors [45]. ErbB2 has been shown to
increase VEGF protein production in cancer cell lines, xenografts,
and in human cancers [46].
S100A7 serves as an important growth regulatory protein in
primary breast malignancies and could possibly control the cellular
responses to EGF partly via the EGFR-dependent actions of EGF.
We have found that epidermal growth factor regulates S100A7
expression. S100A7 mediates events that regulate EGF-induced
migration. Loss of S100A7 expression alters the phosphorylation
state of receptors and inhibits growth factor-induced cell motility
and invasion on fibronectin-coated plates and matrigel-coated
chambers. In addition, downregulation of S100A7 decreases
angiogenesis in matrigel assays. There were definitive osteolytic
lesions observed in mice injected with control cells as compared to
those injected with the S100A7-downregulated cells, and our in
vitro data on the increased size and number of TRAP+ osteoclasts
supports the above results. Furthermore, cytokine analysis revealed
increased expression of IL-8, an osteolytic factor, in the
supernatants of control cells as compared to S100A7-downregu-
lated cells. This study suggests that S100A7 plays an important
role in EGFR-mediated signaling and osteoclast formation in
breast cancer.
Materials and Methods
Cell culture and reagents
MCF-7 and MDA-MB-468 cells were obtained from American
Type Culture Collection (ATCC). The MCF-7 and MDA-MB-
468 cells were grown in DMEM with 10% fetal bovine serum and
with 1% penicillin/streptomycin. Stable S100A7-downregulated
MDA-MB-468 cells and vector control cells were obtained from
Dr. Kornelia Polyak from Dana-Farber Cancer Institute (Boston,
MA) and were maintained in McCoy’s medium with 10% FBS,
1% penicillin/streptomycin, and 2 mg/ml of puromycin. MCF-7
cells were maintained in DMEM media with 10% FBS, and 1%
penicillin/streptomycin. The cells were grown in a humidified
atmosphere of 5% CO2 at 37uC. Cells were seeded in 75 cm
2
flasks with 15 ml of growth medium, unless otherwise mentioned.
All our experiments were done using MDA-MB-468 cell lines
except for Figure 1A, where MCF-7 cell lines were used.
Antibodies were obtained as follows: anti-p-Tyr-EGFR1173/p-
Tyr1248, p-Tyr-Src 416, p-Tyr-SHP2, and b-Actin were all
obtained from Cell Signaling Technology Inc (Danvers, MA) and
anti-p-Tyr-EGFR1173 as well as anti-EGFR were from Santa
Cruz Biotechnology (Santa Cruz, CA). Antibody to S100A7 was
from Imgenex Corp (San Diego, CA). EGF was obtained from
Peprotech Ltd (Rocky Hill, NJ).
Stimulation of cells
MCF-7 and MDA-MB-468 cell lines were grown in 6-well
plates until 80% confluent. The cells were then washed twice with
phosphate-buffered saline (PBS) and were subsequently starved in
0.5% serum overnight at 37uC. The serum-starved cells were
stimulated with various concentrations of EGF at 37uC for
30 minutes. At the end of the stimulation, cells were washed
with PBS and lysed in modified radioimmune precipitation assay
buffer (RIPA) (50 mM Tris-HCl, pH 7.4, 1% Nonidet P-40,
150 mM NaCl, 1 mM phenylmethylsulfonyl fluoride, 10 mg/ml
aprotinin, 10 mg/ml leupeptin, 10 mg/ml antipain, 10 mg/ml
chymostatin, 100 mg/ml TI, 10 mg/ml pepstatin, 10 mM sodium
vanadate, 10 mM sodium fluoride and 10 mM sodium pyrophos-
phate). The lysate was used immediately or stored at 280uC until
further use.
Immunoblotting
For the immunoblotting, aliquots of cell extracts containing
equal amounts of protein were resolved by 4–12% sodium dodecyl
sulphate electrophoresis (SDS-PAGE) (Invitrogen, Carlsbad, CA)
and electroblotted onto nitrocellulose membranes (Bio-Rad,
Hercules, CA).
Cell migration assays
Briefly, MDA-MB-468 cells were washed twice in PBS with
0.5% serum and then resuspended in 0.5% serum containing
McCoy’s medium. A 24-well plate containing 8 mm porosity
inserts (Costar Corporation, Kennebunk, ME) was used for this
experiment to detect MDA-MB-468 cell chemotaxis. The inserts
were precoated with fibronectin (25 mg/ml), and McCoy’s
Medium (600 ml) containing EGF (20 ng/ml) was added to the
bottom well. A volume of 150 ml (containing 1610
5 MDA-MB-
468 cells) from each sample was loaded onto the upper well. The
plates were next incubated for 8 hours at 37uCi n5 %C O 2. After
incubation, the porous inserts were removed carefully, then cells
on the inner surface were wiped with a cotton swab and cells on
the lower surface of the membrane were stained with the Diff-
Quik Stain kit (Dade Diagnostics, Puerto Rico). The surface was
allowed to dry and the number of migrated cells was counted in at
least seven different fields. The results are expressed as the percent
of migrated cells as compared to the control (untreated cells). Each
experiment was performed three times in triplicate.
Chemoinvasion assay
Briefly, MCF-7 cells were detached from the plates with 10 mM
EDTA in PBS, washed twice, and then suspended at 2.5610
6
cells/ml in McCoy’s medium containing 0.5% FBS. A 24-well
plate containing a matrigel coating (Becton Dickinson Biosciences)
was used for this experiment. Cells (150 ml) from each sample were
loaded onto the upper well. The lower well contained 600 mlo f
0.5% FBS McCoy’s medium containing growth factor (EGF,
20 ng/ml). The plates were incubated for 16 hours at 37uCi n5 %
CO2. After incubation, the inserts were removed carefully and the
cells were fixed and stained using the Diff-Quik Stain kit (Dade
Diagnostics). The results are expressed as the percent of migrated
cells as compared to the control (untreated cells).
Culture for osteoclast formation and Transwell assays
Bone marrow cells were obtained from 6 week-old mice after
flushing the long bones and passage of the cells through a 40 mm
nylon mesh. The cells were then washed and incubated in tissue
culture dishes at 37uCi n5 %C O 2 in the presence of M-CSF
(10 ng/ml). After 24 hours in culture, the nonadherent cells were
collected and layered onto Histopaque 1088 (Sigma Aldrich Inc.).
Cells at the gradient interface were collected, washed, and plated
in 24-well tissue culture plates at 5.0610
5 cells/well. After 6 hours,
transwell inserts (8 mm pore size, Corning) containing S100A7
vector control cells or S100A7-downregulated cells (5610
4 cells/
well) were placed in wells containing precursor osteoclasts.
Treatment with RANKL (20 ng/ml) without breast cancer cells
served as a positive control. TRAP staining was performed with
the Leukocyte Phosphatase Kit (Sigma Aldrich Inc.).
Animal model of metastasis
Female CB-17 SCID mice (4 weeks-old) were obtained from
Charles River Laboratories (Boston, MA) and maintained in a
specific pathogen-free barrier animal facility for 1 week prior to
the start of the experiments. MDA-MB-468 cells (S100A7-
expressing control cells and S100A7-downregulated cells) were
S100A7, EGF-Induced Signaling
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to that without antibiotics 24 hours prior to harvesting. Single
suspensions of cells expressing S100A7 (vector control) or S100A7-
downregulated cells were harvested from the subconfluent cultures
by exposure to 0.25% trypsin and 0.02% EDTA. Trypsinization
was stopped by the addition of medium containing 10% FBS
(without antibiotics). Cells were kept at 4uC until use (0–1 hour).
Cell concentration and viability (Trypan blue exclusion, .90%
viability) were determined by a hemocytometer. SCID mice were
anesthetized using Avertin (2.5%), 0.02 mg/kg of bodyweight.
The animal was then shaven over the lower end of the femur and
upper half of the tibia and the injection site prepped with betadine
scrub followed by the use of a 70% alcohol wipe. A 1-cm skin
incision was made on the antero-medial part of the leg and the
muscle was moved using blunt forceps. The bone was drilled using
a microdrill (Roboz Surgical Instruments) with a 0.06 mm caliber
point (vWR Laboratories). Single suspensions of cells expressing
S100A7 or S100A7-downregulated cells (5610
4) in a final volume
of 10 ml were injected into the upper 1/3 of the tibia at a tilted
angle of 45u in the two groups of mice. To prevent leakage of the
cells into surrounding muscles, the injection site was sealed with
surgical bone wax (vWR Laboratories). The wax was allowed to
solidify and the skin was sutured back using black silk. The animals
tolerated the procedure well and no anesthesia-related deaths
occurred during the procedure. One mouse, which acquired a
postoperative infection at the suture site, was treated with betadine
washes and daily dressings with triple antibiotic ointment, and
recovered well. Buprenorphine was used as an analgesic (0.05 mg/
kg/body weight subcutaneously) twice daily for 3–4 days. Mice
from both groups were anesthetized by inhalation using 1.5%
isofluorane in 98.5% oxygen, and Micro-CT scanning was done
using a GE eXplore Micro-CT scanner (GE Healthcare Ltd, UK)
at 93 mm resolution 6 weeks after injection. The mice were then
euthanized using CO2 inhalation, the tibias were dissected out and
scout view radiographs taken with a micro-CT40 scanner at
12 mm resolution from SCANCO Medical AG (Switzerland).
Tumor harvesting and preparation
The mice were euthanized by CO2 inhalation on the 8
th week
and the tibias were resected from both groups of mice, and then
placed in 4% paraformaldehyde at 4uC for 2 days. Micro-CT
scanning with high resolution was done on the bones to confirm
the results of the in vivo imaging, which was done at low resolution.
After the scanning, tumors from both groups of mice were
transferred to decalcifying solution for 7 days at room tempera-
ture. Preparation and staining of frozen sections of the tibias were
done at our Institute’s microscopic histology core facility. The
paraffin sections were analyzed by H & E staining.
Angiogenesis assay
4 week-old CB-17 SCID mice were purchased from Charles
River Laboratories. Growth factor-reduced matrigel was obtained
from BD Biosciences (Bedford, MA), and thawed overnight at 4uC.
The required amount was appropriately calculated and the
remaining aliquots were stored at 280uC. The gel was mixed at
a ratio of 5610
6 cells for 500 ml of matrigel. The mixture was
implanted subcutaneously into two sites at the midline and the
needle was retained for 1–2 minutes to allow the plug to solidify.
The needle was subsequently removed by slow rotation to ensure
that the matrigel did not flow out. After 3 weeks, the mice were
anesthetized using Avertin (2.5%), 0.02 mg/kg of bodyweight and
the matrigel plug was removed. Mice were euthanized with CO2,
and then 0.5 ml to 2 ml of blood was collected from the heart and
placed into heparin-coated tubes for estimation of systemic
hemoglobin. One plug was removed, dipped in embedding
medium (Tissue Tek) and snap-frozen on dry ice. Immunohisto-
chemistry for CD31 was done on the embedded specimens at the
microscopy histology core facility at our Institute. The other plug
was weighed and dissolved in physiological saline (0.9% NaCl).
The tissue was grounded using a Wheaton tissue grinder and the
supernatant was analyzed for hemoglobin content using a
Hemoglobin Assay Kit (containing Drabkin’s reagent) from Sigma
Diagnostics. The results were interpreted as blood volume per unit
weight of matrigel.
Cytokine analysis
The conditioned medium was centrifuged at 14,000 rpm/min
at 4uC to allow the cells and debris to settle down. The upper L
ths
of the sample was removed and analyzed for human IL-8 using an
ELISA kit (R & D Systems).
Statistical analysis
The results are expressed as the means +/2 S.D. of data
obtained from three experiments performed in triplicate. Statis-
tical significance was determined using the Student’s t-test.
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